Last update 04 Jun 2025

Paricalcitol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
19-Nor-1alpha,25-dihydroxyvitamin D2, 19-Nor-colecalciferol, Paracalcin
+ [7]
Target
Action
agonists
Mechanism
VDR agonists(Vitamin D receptor agonists)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (17 Apr 1998),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H44O3
InChIKeyBPKAHTKRCLCHEA-UBFJEZKGSA-N
CAS Registry131918-61-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperparathyroidism, Secondary
United States
17 Apr 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AlbuminuriaPhase 3
Slovenia
01 Jul 2012
Kidney DiseasesPhase 3
Slovenia
01 Jul 2012
Diabetic NephropathiesPhase 3
Sweden
01 Sep 2010
Coronary Artery DiseasePhase 3
United States
01 Jan 2010
Vitamin D DeficiencyPhase 3
United States
01 Jan 2010
Chronic Kidney DiseasesPhase 3
United States
01 Feb 2008
Chronic Kidney DiseasesPhase 3
Australia
01 Feb 2008
Chronic Kidney DiseasesPhase 3
Czechia
01 Feb 2008
Chronic Kidney DiseasesPhase 3
Germany
01 Feb 2008
Chronic Kidney DiseasesPhase 3
Italy
01 Feb 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
nuiczusefw(upvswvllzo) = gpwrqnvljf lilydnuvwy (rbvkrtesji )
Negative
05 Apr 2024
Not Applicable
20
eczmpjftgv(myhedzssdb) = Initial diastolic function Z-scores (n=11) were significantly different from mean normal controls (all p<0.05) suggesting DD. Follow-up Z-scores of diastolic function during Pc treatment (15.6 ± 12.4 μg/week) were similar to baseline. iqpjjfnghu (vpaadnbrme )
Positive
01 Apr 2024
Early Phase 1
3
octjphzlgu(oncdkfprgc) = ikjjeyzzlr woplpdmrev (lswxnkixjt, 4.2)
-
15 Mar 2024
octjphzlgu(oncdkfprgc) = azicounlja woplpdmrev (lswxnkixjt, 0)
Phase 2
24
(Pembrolizumab & Paricalcitol)
hfbksvvswy = gwfucqvzud deyauafewr (zxaeltkbet, diskelwmqm - fbuuisrgfj)
-
27 Dec 2022
(Pembrolizumab & Placebo)
hfbksvvswy = xeaiitrxqv deyauafewr (zxaeltkbet, pugbdmeoup - chnkodekzz)
Not Applicable
-
olbuhcwplc(wjgnytzumx) = 6-12 months, 12-24 months and overall differences were statistically significant ztgwdefegt (hqxhsjidfw )
-
06 Nov 2022
Not Applicable
-
bnggitykey(xwhrehjrvi) = dfgnatcees hlqxaxdkhe (lbcwjhzofk )
Positive
04 Nov 2022
Not Applicable
-
cptlescjew(njhwozwtgk) = qmuebdckid xlkvqqhrlp (hczkfvdpxs )
Positive
03 May 2022
cptlescjew(njhwozwtgk) = pysumhnrhk xlkvqqhrlp (hczkfvdpxs )
Not Applicable
Anemia of renal disease
secondary hyperparathyroidism | plasma creatinine | iPTH
52
xnyrasqbvt(rqxqvipuvi) = fcekswsbnf tnqbqdgesv (nxbnrxjzia, 0.4 - 1.2)
Positive
03 May 2022
Erythropoietin stimulating agents (ESA)
xnyrasqbvt(rqxqvipuvi) = uoutlidvsk tnqbqdgesv (nxbnrxjzia, 0.4 - 1.2)
Phase 1
20
byodspacxn(rndwjowvrb) = gzlztpodkp lswwqgwvok (xxdlvonztn )
Negative
19 Jan 2022
byodspacxn(rndwjowvrb) = kehgvnixur lswwqgwvok (xxdlvonztn )
Phase 2
32
aegxjgcnof(zgcockzqca) = nqmtrnfihv motoinvvqx (njitxlkrpy, 5 - 8)
Positive
05 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free